Capricor and Replimune prep for FDA adcomms, Q2 earnings roll on, Sarepta’s new leader, more

AdComTavneosNegative

AI Analysis

Summary

FDA briefing documents for Capricor Therapeutics and Replimune advisory committee meetings suggest challenging path forward. Sarepta appoints Michael Severino as new CEO while Amgen defends Tavneos; GSK and AstraZeneca outline Q2 earnings results and strategic plans.

Outcome Details

FDA briefing documents indicate uphill battle for Capricor and Replimune therapies

Importance:5/10

Sentiment:

-0.30

AdComFDAearningsleadership_changeregulatory

Related Companies

$GSK $AZN $SRPT $AMGN

Read the original article

Published by BioSpace on July 29, 2026 11:19 AM

Read Original